For men in their mid-seventies, a PSA (prostate-specific antigen) level somewhere around 1.5 to 3.0 ng/mL is typical, though the range of what counts as “normal” is wide enough to surprise most people. A large population-based study of men aged 70 to 74 found a median PSA of 1.6 ng/mL, with the 5th-to-95th percentile spanning from 0.4 all the way up to 7.5 ng/mL.1Medical Journal of Australia. Serum prostate-specific antigen levels in older men: a population-based study That enormous spread hints at why a single number on a lab report can be so hard to interpret, and why the conversation around PSA in older men goes well beyond “is this number too high?”
What PSA Actually Is and Why It Climbs With Age
PSA is a protein produced almost exclusively by the prostate gland. Its biological job has nothing to do with cancer detection: it breaks down proteins in semen that cause it to clot after ejaculation. Some PSA leaks from the prostate into the bloodstream, and that leakage is what a blood test measures.2PubMed. Biology of prostate-specific antigen The amount that leaks depends heavily on the size of the prostate, and the prostate grows steadily throughout a man’s life. By age 75, most men have noticeably larger prostates than they did at 50, which means more tissue producing PSA and more opportunity for it to seep into the blood.
This growth, called benign prostatic hyperplasia, is the single biggest driver of higher PSA readings in older men. One study found that prostate size alone accounted for roughly a quarter of the variation in PSA levels among men with elevated readings, while subclinical inflammation in the gland added another chunk.3PubMed. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels A separate cross-sectional study confirmed a strong positive correlation between PSA and prostate volume in men with benign enlargement, describing the rise as “a direct physiological byproduct of a larger glandular volume.”4PubMed Central. Relationship between prostate-specific antigen and prostate volume in benign enlargement of the prostate: a descriptive cross-sectional study In other words, a 75-year-old with a PSA of 5.0 may simply have a larger-than-average prostate, not cancer.
Why the Old “4.0 Cutoff” Does Not Work Well at 75
For decades, 4.0 ng/mL was treated as a bright line: below it you were fine, above it you needed a biopsy. That threshold was never age-adjusted, and it creates two problems in older men. First, it flags too many men who have nothing wrong. A 75-year-old with a PSA of 5.5 might be well within the normal range for his age group; the population data cited above show that the 95th percentile for men 70 to 74 sits at 7.5, and it rises even higher into the eighties and nineties.1Medical Journal of Australia. Serum prostate-specific antigen levels in older men: a population-based study Second, a fixed cutoff can create false reassurance in younger men whose “normal” range is much tighter. Age-specific reference ranges were proposed to address both problems, but they have never been universally adopted, so many labs still report 4.0 as the upper limit of normal regardless of the patient’s age.
The practical takeaway for a 75-year-old: a reading between roughly 4 and 7 ng/mL does not automatically mean cancer. It means the result needs context, not panic. And a reading of 1.0 or 2.0 is reassuringly low for any age.
Should a 75-Year-Old Be Getting PSA Tests at All?
This is where the medical world gets genuinely divided. The U.S. Preventive Services Task Force recommends against routine PSA-based screening for prostate cancer in men 70 and older.5JAMA. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement The reasoning is not that prostate cancer disappears in older men, but that slow-growing cancers discovered through screening often do not threaten a man’s life within his remaining years, and the harms of treatment (incontinence, erectile dysfunction, surgical complications) can be severe.
Other professional groups take a more nuanced stance. Many urological organizations say that screening can still be reasonable for men over 75 who are in good health and have a life expectancy beyond ten years.6PubMed. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy Long-term data from the European Randomized Study of Screening for Prostate Cancer found that men with higher PSA levels and no prior biopsies could still benefit from continued screening if their life expectancy exceeded ten years.7PubMed. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam A 75-year-old marathon runner with no chronic diseases has a very different risk calculus than a 75-year-old with heart failure and diabetes.
If you are 75 and your doctor orders a PSA test, the conversation that matters most is not the number on the result but what you plan to do with it. If the answer is “nothing, regardless,” there is little point in running the test.
The Overdiagnosis Problem
Prostate cancer is extremely common at autopsy in older men who died of something else entirely. Many of these cancers would never have caused symptoms. When PSA screening identifies one of these slow-growing tumors, it counts as a diagnosis, and the patient often ends up treated for something that would never have hurt him. Estimates of how often this happens vary wildly, from under 2% to as high as 67%, depending on the study and its assumptions.8PubMed Central. Overdiagnosis and Overtreatment of Prostate Cancer The current annual ratio of new prostate cancer diagnoses to prostate cancer deaths is roughly six to one, which gives some sense of how many men are diagnosed with cancers that will not kill them.9PubMed Central. Overdiagnosis of prostate cancer
At 75, the overdiagnosis risk is especially high because remaining life expectancy is shorter and competing causes of death (heart disease, stroke, other cancers) are more likely to intervene first. This does not mean prostate cancer is harmless at 75. Aggressive forms still kill. But the challenge is that a basic PSA test cannot distinguish between a tiger and a pussycat. That task falls to the tools described below.
Tools That Help Distinguish a Worrisome PSA From a Harmless One
When a PSA result comes back elevated, doctors have several ways to figure out whether it signals something that matters before jumping to a biopsy.
Free PSA Ratio
PSA circulates in two forms: bound to other proteins, and unbound (“free”). Cancer tends to produce more of the bound form, so a lower percentage of free PSA relative to total PSA raises suspicion. A large prospective trial found that the median free PSA percentage was about 12% in men with cancer versus 18% in men with benign conditions. Using a cutoff of 25% free PSA detected 90% of cancers in men aged 70 to 75, meaning about one in ten cancers was missed in that age group at that threshold.10JAMA. Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease: A Prospective Multicenter Clinical Trial When your total PSA is in the gray zone, the free PSA ratio can help tip the decision toward or away from biopsy.
PSA Density
PSA density divides the PSA level by the volume of the prostate (measured by ultrasound or MRI). A big prostate naturally produces more PSA, so adjusting for size is logical. Research has found that PSA density outperforms raw PSA in predicting clinically significant prostate cancer, with the strongest evidence pointing to a threshold around 0.15 to 0.20 ng/mL² as a decision point.11Scientific Reports. The use of prostate specific antigen density to predict clinically significant prostate cancer Men with PSA density below 0.09 had only about a 4% chance of harboring clinically significant disease. Longer-term data confirm that a PSA density above 0.15 or 0.20 in men with total PSA between 3 and 10 is associated with a dramatically higher risk of eventually dying from prostate cancer.12PubMed Central. The performance of prostate‐specific antigen density in long‐term prostate cancer‐mortality risk prediction
PSA Velocity
PSA velocity measures how fast your PSA rises over time, typically calculated from at least three readings spread over 18 months or more. The idea is intuitive: a PSA that jumps from 3.0 to 6.0 in a year seems more alarming than one that drifts from 3.0 to 3.5 over two years. In practice, the evidence on velocity is mixed. Some multivariate models show it as a predictor of cancer on repeat biopsy.13PubMed. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy But a review of the broader evidence concluded that PSA velocity should not be used on its own to decide whether someone needs a biopsy or to determine prognosis in an untreated man.14PubMed Central. PSA Velocity and Doubling Time in Diagnosis and Prognosis of Prostate Cancer It adds a piece to the puzzle but is not reliable enough to drive decisions alone.
Medications That Alter Your PSA Reading
If you take finasteride or dutasteride for an enlarged prostate or hair loss, your PSA number is artificially low. These drugs shrink the prostate by blocking the hormone that drives its growth, and as the gland shrinks, PSA drops. The standard clinical rule of thumb is to double the measured PSA to approximate the “true” level, but the real adjustment may not be that simple. Data from the Prostate Cancer Prevention Trial found that the correction factor needed to preserve the median PSA increased from about 2.0 at two years of finasteride use to roughly 2.5 at seven years.15PubMed. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial
To make things more complicated, dutasteride appears to suppress PSA more aggressively than finasteride, which means applying the same “multiply by two” rule to both drugs may underestimate the true PSA in men on dutasteride.16PubMed Central. The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride If you are 75 and have been on one of these medications for years, make sure your doctor knows exactly which drug you take and how long you have been on it. A PSA of 2.0 while taking dutasteride for five years may actually represent a much higher underlying level.
Temporary PSA Spikes From Everyday Activities
PSA is not a fixed number. It fluctuates from day to day, and certain activities can push it up temporarily. The most well-documented example is cycling. A study of men aged 50 and older found that long-distance bicycle riding raised total PSA by an average of about 9.5%, with the increase correlating with both age and distance ridden. Several men in the study crossed the 4.0 threshold after a ride who had been below it before.17PLoS One. Long Distance Bicycle Riding Causes Prostate-Specific Antigen to Increase in Men Aged 50 Years and Over Urinary tract infections, recent ejaculation, and prostate manipulation (including a digital rectal exam performed just before the blood draw) can also cause short-lived bumps. If your PSA comes back borderline, it is worth asking your doctor whether any of these factors could have played a role before repeating the test.
What Happens After an Elevated PSA
A 75-year-old whose PSA comes back at, say, 8.0 is not immediately biopsied in most modern practice. The first step is usually a repeat test after a few weeks to confirm the result, paired with a free PSA ratio and sometimes PSA density if prostate volume is known. If suspicion remains, multiparametric MRI of the prostate has become an increasingly common next step. MRI can identify suspicious lesions and guide a targeted biopsy toward areas most likely to harbor clinically significant cancer, rather than randomly sampling the gland.
MRI is not perfect, though. Its ability to rule out significant cancer when the scan looks clean (the negative predictive value) sits in the range of roughly 76% to 87%, meaning some cancers are missed.18PubMed. Should men undergo MRI before prostate biopsy – CON On the flip side, prostate MRI using the standardized PI-RADS scoring system has been credited with reducing unnecessary biopsies and improving the detection of cancers that actually need treatment, while limiting the discovery of indolent tumors that are better left alone.19PubMed Central. The evolving PI-RADS paradigm For a 75-year-old, this trade-off matters enormously: the goal is to find the cancers worth treating while avoiding the cascade of biopsies, anxiety, and potential side effects that come with discovering cancers that would never have caused harm.
Racial Differences in PSA Screening and Outcomes
PSA levels and prostate cancer risk are not uniform across racial groups. Black men develop prostate cancer at higher rates, tend to be diagnosed at younger ages, and are more likely to have aggressive disease. Part of the disparity in outcomes appears linked to differences in screening access. Research has shown that Black men diagnosed with prostate cancer were more likely to have had longer intervals between PSA tests, or no screening at all, before diagnosis. When the analysis accounted for those screening gaps, the racial difference in being diagnosed with advanced-stage disease shrank to a point where it was no longer statistically significant.20PubMed Central. Racial differences in PSA screening interval and stage at diagnosis The implication is that equitable screening access could narrow the survival gap, though biological differences in cancer aggressiveness likely play a role too.
For a Black man turning 75, the blanket recommendation against screening may deserve more pushback than it gets. Several professional guidelines already suggest that higher-risk groups, including Black men and those with a family history, discuss continued screening with their doctors even past the age cutoffs used in population-level recommendations.
Newer Blood-Based Tests Beyond Standard PSA
Standard PSA testing has been around since the late 1980s, and its limitations are well known. In recent years, several commercially available panels have tried to improve on it. The Prostate Health Index (phi) combines total PSA, free PSA, and a PSA precursor form called p2PSA into a single score that outperforms any of those markers alone. A conceptually similar test, the 4Kscore, uses a panel of four kallikrein markers. Both have been validated in U.S. and European populations and are included as options in major clinical guidelines for men facing a biopsy decision.21PubMed Central. The Prostate Health Index: Its Utility In Prostate Cancer Detection
These tests sit between a basic PSA blood draw and an MRI in terms of cost and complexity. They are most useful in the gray zone, when total PSA is mildly elevated and the question is whether to proceed to imaging or biopsy. For a 75-year-old with a PSA of 6 and an enlarged prostate, a phi or 4Kscore result that comes back low can provide real reassurance and help avoid an unnecessary procedure. Availability varies by region and insurance coverage, but they are increasingly part of the diagnostic toolkit, and worth asking about if your PSA is elevated and you want more information before deciding on next steps.